Skip to content
Register Sign in Wishlist

Translational Medicine and Drug Discovery


Bruce H. Littman, Ann Taylor, Roberto Calle, John Millar, Gregory Gaich, David E. Moller, S. Aubrey Stoch, Gerard J. Marek, Dominic G. Spinella, Pfizer Global Research and Development, Johannes T. Tauscher, Adam Schwarz, Ole J. Bjerrum, Hans H. Linden, Elizabeth Gribble Walker, David B. Lee, Thaddeus H. Grasela, Jill Fiedler-Kelly, Robert Slusser, Mervyn Turner
View all contributors
  • Date Published: October 2014
  • availability: Available
  • format: Paperback
  • isbn: 9781107435940

£ 49.99

Add to cart Add to wishlist

Other available formats:
Hardback, eBook

Looking for an inspection copy?

This title is not currently available on inspection

Product filter button
About the Authors
  • This book, edited by two innovative leaders in the field, focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry. Translational medicine seeks to translate biological and molecular knowledge of disease and how drugs work into innovative development strategies that reduce the cost and increase the speed of delivering new medicines for patients. This book outlines general strategies, biomarker development, imaging tools, translational human models and examples of their application to real drug development. The latest thinking is presented by researchers from many of the world's leading drug development companies, including Pfizer, Merck, Eli Lilly, Abbott and Novartis, as well as academic institutions and public-private partnerships that support translational research. This book is essential for anyone interested in translational medicine from a variety of backgrounds: university institutes, medical schools, pharmaceutical companies and drug development researchers and decision-makers.

    • Discusses the new field of translational medicine and includes contributions from experts from the world's leading drug development companies and institutes, including Pfizer, Merck, Eli Lilly, Abbott and Novartis
    • Contains current research information and real drug project and biomarker development examples
    • Describes how the discipline of translational medicine has evolved to address the key problem in drug development today, namely unsustainable high-cost phase II attrition
    Read more

    Reviews & endorsements

    'This is an important book in a relatively new and growing field. Anyone engaged in advanced research designed to bring new drugs and biologics to market will find it valuable.' Drug Information Journal

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity


    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?


    Product details

    • Date Published: October 2014
    • format: Paperback
    • isbn: 9781107435940
    • length: 384 pages
    • dimensions: 254 x 178 x 20 mm
    • weight: 0.67kg
    • contains: 49 b/w illus. 16 tables
    • availability: Available
  • Table of Contents

    Part I. Translational Medicine: History, Principles and Application in Drug Development:
    1. Overview of translational medicine and drug development Bruce H. Littman
    2. Concepts and case studies: diabetes Ann Taylor and Roberto Calle
    3. Challenges in atherosclerosis John Millar
    4. Obesity: new mechanisms and translational paradigms Gregory Gaich and David E. Moller
    5. Bone disorders: case studies of translational research S. Aubrey Stoch
    6. Case studies in neuroscience: unique challenges and examples Gerard J. Marek
    7. Translational medicine in oncology Dominic G. Spinella
    Part II. Biomarkers and Public-Private Partnerships:
    8. Biomarker validation and application in drug development Pfizer Global Research and Development
    9. Application of imaging methods in translational medicine Johannes T. Tauscher and Adam Schwarz
    10. European innovative medicines initiative Ole J. Bjerrum and Hans H. Linden
    11. Critical path institute and the predictive safety consortium Elizabeth Gribble Walker
    12. The biomarker consortium David B. Lee
    Part III. Future Directions:
    13. Improving the quality and productivity of pharmacometric modeling and simulation activities - the foundation for model-based drug development Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser
    14. Embracing change: a pharmaceutical industry guide to the 21st century Mervyn Turner.

  • Editors

    Bruce H. Littman, Translational Medicine Associates
    Rajesh Krishna, PhD, FCP, is an area lead director in early stage development at Merck Research Laboratories. Dr Krishna is the editor of three books on new drug development besides publishing over 120 articles and oral/poster presentations. He has served as a section editor for the Journal of Clinical Pharmacology, associate editor for BMC Clinical Pharmacology and an editorial board member for BMC Medicine. He is a Fellow of the American College of Clinical Pharmacology and the American Association of Pharmaceutical Scientists, where he is the current Chair of the Clinical Pharmacology and Translational Research section. He is an affiliate member of the Institute of Translational Medicine and Therapeutics at the University of Pennsylvania.

    Rajesh Krishna, Merck Research Laboratories
    Bruce Littman, MD, is the founder of Translational Medicine Associates, LLC, as well as former co-chair and current member of the Inflammation and Immunity Steering Committee of the Biomarker Consortium. Prior to starting his own company, Dr Littman was the Vice President and Global Head of Translation Medicine at Pfizer Inc. where he worked for nineteen years, first in experimental medicine and then translational medicine. He was also a faculty member of Virginia Commonwealth University School of Medicine for thirteen years. He is a Founding Fellow of the American College of Rheumatology, former President of the Virginia Society of Rheumatologists and a Fellow of the American College of Physicians.


    Bruce H. Littman, Ann Taylor, Roberto Calle, John Millar, Gregory Gaich, David E. Moller, S. Aubrey Stoch, Gerard J. Marek, Dominic G. Spinella, Pfizer Global Research and Development, Johannes T. Tauscher, Adam Schwarz, Ole J. Bjerrum, Hans H. Linden, Elizabeth Gribble Walker, David B. Lee, Thaddeus H. Grasela, Jill Fiedler-Kelly, Robert Slusser, Mervyn Turner

Sign In

Please sign in to access your account


Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner Please see the permission section of the catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

Join us online

This site uses cookies to improve your experience. Read more Close

Are you sure you want to delete your account?

This cannot be undone.


Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

Please fill in the required fields in your feedback submission.